[
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−7",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−8",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−9",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−11",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−12",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−12",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−13",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−13",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−14",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−14",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−15",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤10−15",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "≤5×10−10",
        "unit": "M",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤10−4",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤5×10−5",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤10−5",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤5×10−6",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤10−6",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤5×10−7",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Interleukin-6 ",
        "protein_target_name": "IL-6",
        "binding_metric": "off-rate",
        "value": "≤10−7",
        "unit": "S−1",
        "is_logarithmic": false,
        "raw_mentions": "In one embodiment of the invention, the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with a dissociation constant (K<sub>D</sub>) of less than or equal to 5×10<sup>−7</sup>, 10<sup>−7</sup>, 5×10<sup>−8</sup>, 10<sup>−8</sup>, 5×10<sup>−9</sup>, 10<sup>−9</sup>, 5×10<sup>−10</sup>, 10<sup>−10</sup>, 5×10<sup>−11</sup>, 10<sup>−11</sup>, 5×10<sup>−12</sup>, 10<sup>−12</sup>, 5×10<sup>−13</sup>, 10<sup>−13</sup>, 5×10<sup>−14</sup>, 10<sup>−14</sup>, 5×10<sup>−15 </sup>or 10<sup>−15</sup> M.\nPreferably, the anti-IL-6 antibodies and fragments thereof bind IL-6 with a dissociation constant of less than or equal to 5×10<sup>−10</sup> M.\nIn another embodiment of the invention, the anti-IL-6 activity of the anti-IL-6 antibodies of the present invention, and fragments thereof having binding specificity to IL-6, bind to IL-6 with an off-rate of less than or equal to 10<sup>−4 </sup>S<sup>−1</sup>, 5×10<sup>−5 </sup>S<sup>−1</sup>, 10<sup>−5 </sup>S<sup>−1</sup>, 5×10<sup>−6 </sup>S<sup>−1</sup>, 10<sup>−6 </sup>S<sup>−1</sup>, 5×10<sup>−7 </sup>S<sup>−1</sup>, or 10<sup>−7 </sup>S<sup>−1</sup>."
    },
    {
        "molecule_name": "Immunoglobulin",
        "protein_target_name": "IL-6",
        "binding_metric": "Kd",
        "value": "single to double digit pM",
        "unit": "pM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe antibodies have high affinity towards IL-6 (single to double digit pM Kd) and demonstrate potent antagonism of IL-6 in multiple cell-based screening systems (T1165 and HepG2)."
    }
]